Veterinary medicine can borrow tools from human practice. The current approach is not universally applicable for each molecule as it requires the availability of an existing compound with well-defined properties.
Selecting the perfect antibody from species-specific libraries. The synthetic nature of the library allows quick format changes and optimization processes such as affinity maturation.
The phage display method offers full control over the antibody selection process and the possibility to direct the selection towards a desired candidate profile.
The final candidate has an optimal functionality and a low risk for immunogenicity.
Collection of billions of fully species specific antibodies
Selection of ‘perfect fit’
The final therapeutic
Collection of billions of fully species specific antibodies
Selection of ‘perfect fit’
The final therapeutic
The adivo technology platform allows de-novo identification of a panel of antibodies to select a drug candidate with optimal functionality, developability and low risk of immunogenicity.
We offer an in-depth expertise in antibody generation and lead-candidate selection.
For partnering enquiries, please contact us at bd@adivo.vet
A pharmacist by training and with a PhD in Immunology from the Ludwig-Maximilians-Universität München, Kathrin brings entrepreneurial spirit and a track record in navigating therapeutic partnerships successfully to adivo. Motivated by personal experience with her dog Caesar, who fought with cancer for many years, she decided to apply her professional knowledge to solve a key problem in veterinary healthcare - the lack of species-specific immunotherapies for pets.
Prior to founding adivo in 2018, she held several positions within the R&D organization as well as the Alliance Management team at MorphoSys, a world-leading human antibody therapeutics company. The expertise gained through shepherding multiple therapeutic projects in close collaboration with international pharma partners supports adivo in establishing a leading companion animal therapeutics pipeline. At adivo, Kathrin is driving the financing and business development strategy of the company and is managing adivo’s existing alliances.
Kathrin owns two dogs, Canela and Erly.
A biochemist and biochemical engineer by training and with a PhD from the Ludwig-Maximilians-Universität München, Markus combines profound project management and leadership skills. Before co-founding adivo, he was responsible for planning and implementing tailored strategies to discover and develop human therapeutic antibodies at MorphoSys including the staffing and management of high-performing project teams.
At adivo, Markus is leading the transition of antibody lead candidates from the company´s discovery platform into clinical development in close collaboration with a variety of internal and external parties.
Markus adopted a shelter dog called Leni.
A biochemist by training and with a PhD in Structural Biology and Protein Chemistry and an MBA from the Technical University of Munich, Phillip was appointed Chief Scientific Officer of adivo in 2022 after having joined the company in 2019. He combines profound expertise in rational protein design with high throughput protein engineering from his time as a postdoctoral researcher at Brandeis University in Boston, USA.
At adivo, Philipp drives the target identification process and technology development, as well as antibody discovery for both proprietary and partnered programs.
/
To strengthen our team, we are looking for highly motivated humans with a passion for pets. If you want to be an integral part of a growing team in a start-up company, feel free to contact us.
Antibody Discovery Team
In the case you don’t see yourself in these positions we are always on the look out for motivated and talented people so feel free to send your PDF application at career@adivo.vet or follow us on linkedIn to find out about our new openings in the future.
adivo GmbH
Zeppelinstraße 4
82178 Puchheim
Germany
For business development and partnering enquiriesbd@adivo.vet
For media, investor, career or general information info@adivo.vet
The company is located in the Innovation and Start-Up Center for Biotechnology (IZB) in Martinsried near Munich, offering a perfect place to implement new ideas and connect with other founders and biotech companies.